Drugs / Avdoralimab
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03665129 | Sep 2018 → Feb 2021 | cancer | Innate Pharma | Terminated | No outcome recorded |
| Phase 1 | NCT01955603 | Sep 2013 → Oct 2014 | rheumatoid arthritis | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01611688 | Jun 2012 → Jun 2013 | rheumatoid arthritis | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT04563923 | Oct 2020 → Apr 2023 | bullous pemphigoid | Centre Hospitalier Universitaire de Nice | Completed | No outcome recorded |
| Phase 2 | NCT04371367 | Apr 2020 → Mar 2021 | COVID-19 | Assistance Publique Hopitaux De Marseille | Completed | Missed primary |
| Phase 2 | NCT04333914 | Apr 2020 → Jul 2021 | COVID-19 | Centre Leon Berard | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2021-07-06 | Innate Pharma | Results Update on Avdoralimab Phase 2 FORCE Trial in COVID-19 Patients with Severe Pneumonia innate-pharma.com ↗
Investigator-sponsored FORCE trial did not meet primary endpoints |
| 2019-11-06 | Innate Pharma | Results Innate Pharma announces preclinical data presentations at SITC 2019 innate-pharma.com ↗ |
| 2019-10-01 | Innate Pharma | Results Innate Pharma presents early clinical data on IPH5401 and monalizumab at the ESMO 2019 congress innate-pharma.com ↗
Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that new data on IPH5401 and monalizumab were presented at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain. |
| 2017-09-11 | Innate Pharma | Results ICI conference 2017: new preclinical data further strengthen the rationale of IPH5401 and monalizumab for cancer treatments and in combination with anti-PD-1/PD-L1 innate-pharma.com ↗
Moreover, the data show that the combined administration of anti-C5aR with anti-PD-1 reduced tumor growth. |
All press releases naming this drug 7 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Avdoralimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04333914 ↗ |
| Known as | Anti-c5ar-215 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594463 ↗ |
| Known as | IPH5401 | “Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody” NCT04563923 ↗ |
| Known as | NN-8210 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594463 ↗ |
| Known as | NNC0215-0384 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01611688 ↗ |
| Action | Inhibit | “IPH5401 (anti C5aR)” NCT03665129 ↗ |
| Modality | Monoclonal antibody | “avdoralimab (an anti-C5aR1 mAb)” PMID 36218354 ↗ Oct 2022 |
| Route | Intravenous | “I.v.(intravenous) dose-escalation.” NCT01611688 ↗ |
| Target | C5AR1 | “avdoralimab (an anti-C5aR1 mAb)” PMID 36218354 ↗ Oct 2022 |